Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423607 | 0.85 | KDM4E (0.53) | LDHAESR1ESR2MMEALDH1A1 | |
| SCHEMBL6423606 | 0.85 | KDM4E (0.53) | LDHAESR1ESR2MMEALDH1A1 | |
| SCHEMBL10964998 | 0.81 | ESR1 (0.63) | LDHAESR1ESR2MAPTNPC1 | |
| SCHEMBL9416618 | 0.81 | MMP1 (0.55) | LDHAALDH1A1LMNAKMT2AMMP1 | |
| SCHEMBL31438951 | 0.81 | FOS (0.57) | LDHAALDH1A1NPSR1CYP3A4TSHR | |
| SCHEMBL30873063 | 0.81 | ALOX15 (0.57) | LDHALMNACYP3A4TSHRNFKB1 | |
| SCHEMBL27183341 | 0.81 | ALOX15 (0.57) | LDHALMNACYP3A4TSHRNFKB1 | |
| SCHEMBL27586425 | 0.80 | ESR1 (0.54) | LDHAESR1ESR2 | |
| SCHEMBL29184136 | 0.79 | EPHX1 (0.62) | LDHAALDH1A1LMNANPSR1ADRB2 | |
| SCHEMBL29184114 | 0.79 | EPHX1 (0.62) | LDHAALDH1A1LMNANPSR1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1251738-B1 | NOVEL DIPHENYLETHYLENE COMPOUNDS | THERACOS INC (US) | 2008-12-17 | — | — | EP | claimed |
| CN-100484400-C | diphenylethylene compounds | CALYX THERAPEUTICS INC (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1251738-B1 | NOVEL DIPHENYLETHYLENE COMPOUNDS | THERACOS INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20040259938-A1 | Novel dipheylenthylene compounds | CALYX THERAPEUTICS, INC. | 2004-12-23 | — | — | US | disclosed |
| CN-1437441-A | novel diphenylethylene compounds | CALYX THERAPEUTICS INC (US) | 2003-08-20 | — | — | CN | disclosed |
| US-20020002200-A1 | Diaromaticethylene compounds orally effective anti-diabetic agents that may normalize glucose and lipid metabolism in a patient with diabetes | THERACOS, INC. | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259938-A1 | Novel dipheylenthylene compounds | LIPE, GPR119, PNLIP | LDHA 783/4885ESR1 1818/4885ESR2 759/4885 |
| US-20020002200-A1 | Diaromaticethylene compounds orally effective anti-diabetic agents that may normalize glucose and lipid metabolism in a patient with diabetes | LIPE, GPR119, PNLIP | LDHA 215/4885ESR1 1993/4885ESR2 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.